secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyra Therapeutics, Inc. (LYRA)
CIK:        0001327273
Form:       8-K
Filed at:   2022-06-17T23:59:59+00:00
Accession:  0001564590-22-023497
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Lyra Therapeutics stockholders elect three Class II directors and ratify auditor at annual meeting
--------------------------------------------------------------------------------

- Michael Altman, C. Ann Merrifield, and Harlan Waksal elected as Class II directors with votes for 19.7M-19.8M each; 2.5M broker non-votes.
- Ratification of BDO USA as independent auditor for FY2022: 22.3M for, 25.5K against, 16.5K abstained.
- Approximately 70.19% of outstanding shares (22.3M of ~31.8M) represented at the meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1327273/000156459022023497/0001564590-22-023497-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1327273/000156459022023497/lyra-8k_20220616.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-023497

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer